Value Drug Company V. Takeda Pharmaceuticals, U.S.A, Inc., Et al, No. 21-cv03500) (E.D PA.)
Faruqi & Faruqi represents a proposed class of direct purchasers of Takeda Pharmaceuticals' Colcrys, a prescription drug used for the treatment of Familial Mediterranean Fever and for the treatment and prevention of gout flares. The complaint alleges ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Bystolic Antitrust Litig., No. 20-cv-05735 (S.D.N.Y)
In the Bystolic case, Faruqi & Faruqi represents a proposed class of direct purchasers of Forest Laboratories' (now AbbVie) blood pressure drug, Bystolic. The complaint alleges that Forest entered into reverse payment agreements with several would-be ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re EpiPen Direct Purchaser Litig., No. 20-cv-0827 (D. Minn.)
In the EpiPen case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Mylan's EpiPen, an epinephrine auto-injector used to treat anaphylaxis (i.e. allergic reactions). The complaint alleges that Mylan ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Seroquel XR (Extended Release Quetiapine Fumarate) Litig., No. 20-cv-01076 (D. Del.)
In the Seroquel case, Faruqi & Faruqi represents a proposed class of direct purchasers of AstraZeneca's Seroquel XR, a prescription drug treatment for schizophrenia, bipolar disorder, and depression. The complaint alleges that AstraZeneca entered into ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Novartis and Par Antitrust Litig., No. 18-cv-04361 (S.D.N.Y.)
In the Exforge case, Faruqi & Farqui represents a pharmaceutical wholesaler and a proposed class of direct purchasers of the hypertension drug, Exforge. The complaint alleges that Novartis entered into a reverse payment agreement with Par to delay Par's ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Zetia (Ezetimibe) Antitrust Litig., No. 18-md-02836 (E.D. Va.)
In the Zetia case, Faruqi & Faruqi represents a class of direct purchasers of Merck & Co.'s Zetia (ezetimibe), a drug used to treat high cholesterol. The case alleges that Merck entered into an unlawful reverse payment settlement with generic manufacturers ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Intuniv Antitrust Litig., No. 16-cv-12653 (D. Mass.)
In the Intuniv case, Faruqi & Faruqi represents a class of direct purchasers of Shire's Intuniv (guanfacine), a prescription drug used to treat attention deficit hyperactivity disorder. The class also includes direct purchasers of generic versions of ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Generic Pharmaceuticals Pricing Antitrust Litig., MDL No. 2724 (E.D. Pa.)
Faruqi & Faruqi represents a proposed class of generic drug purchasers in this action alleging that dozens of generic pharmaceutical manufacturers engaged in an unlawful scheme to fix, maintain, and stabilize prices, rig bids, and engage in market and ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Lamictal Direct Purchaser Antitrust Litig., No. 12-00995 (D.N.J.)
In the Lamictal case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of SmithKline Beacham's Lamictal, prescription drugs used to treat epilepsy, bipolar disorder and other medical conditions. The class ...
Joseph T. Lukens, Peter Kohn at New York office
In re Niaspan Antitrust Litig., No. 13-cv-1820 (E.D. Pa.)
In the Niaspan case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott Laboratories' triglyceride drug, Niaspan, whose active ingredient is niacin (vitamin B6). Faruqi & Faruqi filed the first direct ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litig., No. 13-cv-2445 (E.D. Pa.)
In the Suboxone case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a class of direct purchasers of Reckitt Benckiser's opioid addiction drug, Suboxone. The class alleges that Reckitt took several actions to suppress competition from generic ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Lipitor Antitrust Litigation, No. 12-2389 (PGS/DEA) (D.N.J.)
In this case, nicknamed Lipitor, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Pfizer's branded blockbuster cholesterol drug Lipitor (atorvastatin calcium), and direct purchasers of generic Lipitor ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Effexor XR Antitrust Litigation, No. 11-cv-5479 (D.N.J.)
In the Effexor XR case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Wyeth's (now Pfizer's) branded antidepressant drug Effexor XR (extended-release venlafaxine hydrochloride capsules). The class ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re AndroGel Antitrust Litigation (II), 09-md-2084 (N.D. Ga.)
In the Androgel litigation, Faruqi & Faruqi, LLP represent a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott's branded testosterone drug, AndroGel. The case alleges that Abbott's predecessor filed baseless patent litigation ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office